Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of orelabrutinib in adults with systemic lupus erythematosus
CTR20223230Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Orelabrutinib arm with Placebo arm (2 arms). Primary endpoint: SLE Responder Index-4 response rate. Started Apr 2023; status: active.
02
Drugs
orelabrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20223230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223230.